REGISTERED NUMBER: 12930143 (England and Wales)

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

CONSERV BIOSCIENCE LIMITED

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTORS:

K R Duncan

R J Huston

REGISTERED OFFICE:

The Walbrook Building

25 Walbrook

London

EC4N 8AF

REGISTERED NUMBER:

12930143 (England and Wales)

ACCOUNTANTS:

TC Group

Baird House

Seebeck Place

Knowlhill

Milton Keynes

Buckinghamshire

MK5 8FR

FIXED ASSETS

Intangible assets

4

11,006

11,845

Tangible assets

5

71,211

75,534

82,217

87,379

CURRENT ASSETS

Debtors

6

208,525

172,149

Cash at bank

142,733

30,374

351,258

202,523

CREDITORS

Amounts falling due within one year

7

109,008

74,636

NET CURRENT ASSETS

242,250

127,887

TOTAL ASSETS LESS CURRENT LIABILITIES

324,467

215,266

CREDITORS

Amounts falling due after more than one year

8

300,000

346,532

NET ASSETS/(LIABILITIES)

24,467

(131,266

)

CAPITAL AND RESERVES

Called up share capital

1

1

Retained earnings

24,466

(131,267

)

24,467

(131,266

)

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 2 July 2025 and were signed on its behalf by:

K R Duncan - Director

1.	STATUTORY INFORMATION

Conserv Bioscience Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets

The expenditure on acquiring Intellectual Property is treated as an intangible fixed asset and amortised over their estimated economic lives. Amortisation will commence with the commercial production or application of the intangible asset. Provision is made for any impairment.

Patents & licences - 20 Years

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

20% on reducing balance

Computer equipment

-

33% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred, except where the development expenditure incurred on an individual project is carried forward when its future recoverability can reasonably be regarded as assured.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Grants

Grants that are received in respect of expenses or losses already incurred by the entity are recognised in profit and loss in the period when the grant becomes receivable.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2023 - 2 ) .

4.	INTANGIBLE FIXED ASSETS

Other

intangible

assets

£

COST

At 1 January 2024

and 31 December 2024

11,845

AMORTISATION

Charge for year

839

At 31 December 2024

839

NET BOOK VALUE

At 31 December 2024

11,006

At 31 December 2023

11,845

5.	TANGIBLE FIXED ASSETS

Plant and

Computer

machinery

equipment

Totals

£

£

£

COST

At 1 January 2024

92,219

2,639

94,858

Additions

3,579

3,739

7,318

At 31 December 2024

95,798

6,378

102,176

DEPRECIATION

At 1 January 2024

18,444

880

19,324

Charge for year

10,878

763

11,641

At 31 December 2024

29,322

1,643

30,965

NET BOOK VALUE

At 31 December 2024

66,476

4,735

71,211

At 31 December 2023

73,775

1,759

75,534

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Other debtors

208,525

172,149

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade creditors

1,963

41,227

Amounts owed to group undertakings

19,838

-

Taxation and social security

8,708

13,661

Other creditors

78,499

19,748

109,008

74,636

8.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

2024

2023

£

£

Amounts owed to group undertakings

300,000

346,532

9.	RELATED PARTY DISCLOSURES

As at the balance sheet date £319,838 was due by the company to Peptcell Limited (2023: £346,532).

10.	ULTIMATE CONTROLLING PARTY

Peptcell Limited is the company's ultimate parent undertaking.